Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Anne E. Hammer"'
Autor:
Hermine I Brunner, Nicolino Ruperto, Clarissa A Pilkington, Damon L Bass, Mohamed Okily, Holly Quasny, Fengchun Zhang, Syuji Takei, Carlos Abud-Mendoza, Diego O Viola, Beulah N Ji, David A Roth, Masaaki Mori, Sandra Navarra, Reema Syed, Gina Eriksson, Anne E Hammer
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/c028e3050036431689b5ae65af0ceb84
Autor:
David M. Roth, Deborah M. Levy, Michael Henrickson, Inmaculada Calvo Penades, Carlos Abud-Mendoza, Michael Shishov, Vyacheslav Chasnyk, Julia E Calderon, Antonio Nino, Diego O Viola, Alina Boteanu, Manuel A. Ferrandiz, Maria Gastanaga, Herbert Struemper, Mei-Lun Wang, Anne E. Hammer, Kenneth L. Clark, Hermine I. Brunner, Beulah Ji, Vladimir Keltsev, Nicolino Ruperto, Daniel J. Lovell, Jordi Anton, Damon Bass, Alberto Martini
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThis ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE).MethodsPatients (5 to 17 years) wer
Autor:
Reema Syed, Hermine I. Brunner, Beulah Ji, M. Okily, Carlos Abud-Mendoza, Gina Eriksson, Masaaki Mori, Sandra V. Navarra, Diego O Viola, Anne E. Hammer, Syuji Takei, Fengchun Zhang, Holly Quasny, Damon Bass, Nicolino Ruperto, Richard Furie, David M. Roth, Clarissa Pilkington
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
RMD Open
RMD Open
ObjectiveTo assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE).MethodsWe performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus stand
Publikováno v:
Poster presentations.
Background Belimumab is approved as add-on therapy for patients ≥5 years with active, autoantibody-positive systemic lupus erythematosus (SLE).1 The PLUTO trial (NCT01649765) demonstrated safety and efficacy of belimumab in children with SLE2 as ge
Autor:
N.L. Fox, J. Groark, Anne E. Hammer, David M. Roth, Morton Scheinberg, Andreas Schwarting, Damon Bass, David Gordon, Andrea Doria, C Kleoudis, William Stohl
Publikováno v:
Lupus
Objective To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. Methods This was a 24-week, open-label extension following a 52-week, double-blind, placebo-
Publikováno v:
Annals of the Rheumatic Diseases. 80:596.1-596
Background:Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterised by persistent B-cell activation. Belimumab (BEL), a monoclonal antibody that inhibits B-lymphocyte stimulator, is approved in patients aged ≥5 years with a
Autor:
F. Zhang, M. Daniels, Anne E. Hammer, Toshiya Atsumi, P. Meizlik, Daniel J. Wallace, David M. Roth, H. Quasny, Andreas Schwarting
Publikováno v:
Annals of the Rheumatic Diseases. 80:596.2-597
Background:Belimumab (BEL), a monoclonal antibody that antagonizes B-lymphocyte stimulator, was first approved in 2011 for active, autoantibody-positive systemic lupus erythematosus (SLE). BEL has been studied for over 10 years; and while safety data
Autor:
Morton Scheinberg, David Gordon, Andreas Schwarting, Anne E. Hammer, David M. Roth, N.L. Fox, William Stohl, J. Groark, C Kleoudis, Damon Bass, Masato Okada, Andrea Doria
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods Patients with moderate-to-severe SLE (score of ≥8 on the Safety of Estrogens in Lupus Erythematosus National Ass
Autor:
J. Groark, David Gordon, N.L. Fox, Anne E. Hammer, Saira Z Sheikh, Herbert Struemper, David M. Roth
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective: To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods: Patients previously treated with belimumab self-administered belimumab 200 mg SC weekly for
Autor:
Damon Bass, Hermine I. Brunner, Herbert Struemper, Daniel J. Lovell, Anne E. Hammer, Antonio Nino, Michael Shishov, Mei-Lun Wang, Beulah Ji, Kenneth L. Clark, Vladimir Keltsev, Julia Calderon Gallegos, Alberto Martini, Vyacheslav Chasnyk, Jordi Anton, David M. Roth, Manuel A. Ferrandiz, Alina Boteanu, Carlos Abud-Mendoza, Inmaculada Calvo, Maria Gastanaga, Deborah M. Levy, Nicolino Ruperto, Diego O Viola, Michael Henrickson
Publikováno v:
Poster Presentations.
Background: Belimumab (BEL), a monoclonal antibody targeting the B-lymphocyte stimulator, is approved in adults with active systemic lupus erythematosus (SLE). This is the first clinical trial of belimumab in pediatric patients with childhood-onset S